Executive Summary: Chronic Disease Interception and GLP-1 Cost Management: Programs That Change the Trajectory
LFP-10.10 — The Cost Management Frontier#
Most cost management strategies in this series address the current plan year. Chronic disease interception and GLP-1 cost management operate on a different timeline. They change what happens next year and the year after. The member whose diabetes remains well managed does not develop nephropathy. The member on a well-structured GLP-1 protocol loses weight, improves cardiovascular markers, and reduces future MSK, cardiovascular, and diabetes claims. The long-term return exceeds the current-year savings because the intervention changes the cost trajectory rather than managing a single event.
The claims data signals are visible to any TPA that looks for them: rising hemoglobin A1c, increasing blood pressure medication dosages, weight gain correlated with new MSK claims, pharmacy refill gaps signaling declining adherence. A member with well-controlled Type 2 diabetes generates approximately $10,000 to $16,000 in annual medical costs according to the American Diabetes Association’s 2023 analysis. A member whose diabetes progresses to nephropathy or cardiovascular complications can generate $50,000 to $100,000 or more in a single plan year. A single diabetes-related amputation costs $70,000 to $120,000 in surgical and post-surgical care. Digital chronic disease management vendors have documented that interception works. Omada Health reported cost savings of approximately $1,169 per member per year with diabetes program ROI turning positive at six to twelve months and reaching 2.7:1 through year two. Livongo reported savings of $1,908 per participant per year.
GLP-1 medications cost $8,000 to $16,000 per user per year at list price. USI data shows that adult plan members with Type 2 diabetes on a GLP-1 cost employers $21,758 per year on average versus $13,961 for members who do not take these drugs. A single member on GLP-1 medication at $12,000 per year represents 3 to 4 percent of a typical 25-person plan’s claims fund. The cost management strategy is not exclusion; it is structured access. Prior authorization criteria tied to BMI thresholds or confirmed comorbidities, step therapy requiring first-line treatments before GLP-1 approval, and outcomes-based continuation criteria requiring documented clinical response all control utilization without denying appropriate access. Only 14 percent of GLP-1 users remain on therapy after three years; the stop-start pattern produces the worst financial outcome. Wraparound programs combining medication with behavioral coaching and nutrition support improve adherence and outcomes, but only 14 percent of employers currently offer them.
For a 25-person plan, if two members avoid significant chronic disease complications through interception, gross savings range from $70,000 to $130,000 over two years. GLP-1 pharmacy channel optimization and international pharmacy access can reduce one member’s annual drug cost from $16,000 to $10,000 to $12,000. Implementation costs for chronic disease management vendor fees and GLP-1 administration run $6,000 to $18,000 annually. The current-year savings alone may not justify the investment on a single small plan. The future-year savings and the book-level impact across the TPA’s full portfolio are where the strategy produces its return.